Favipiravir, also known as T-705 or Avigan, is an experimental antiviral drug being developed by Toyama Chemical of Japan with activity against many RNA viruses. Like some other experimental antiviral drugs (T-1105 and T-1106), it is a pyrazinecarboxamide derivative. Favipiravir is active against influenza viruses, West Nile virus, yellow fever virus, foot-and-mouth disease virus as well as other flaviviruses, arenaviruses, bunyaviruses and alphaviruses. Activity against enteroviruses and Rift Valley fever virus has also been demonstrated.
Favipiravir is an antiviral molecule that is being developed for the treatment of inﬂuenza virus infections but that exerts also activity against a number of unrelated RNA viruses, including bunyaviruses, arenaviruses and ﬂaviviruses. T-705 is converted to its active form T-705 ribofuranosyl 5’-tri-phosphate by cellular enzymes.
This is collected by BOC Sciences.
This article duplicated from： https://www.bocsci.com/t-705-cas